Evaluation of Mapmydiabetes, the NICE-endorsed diabetes self-management education platform

“糖尿病是一个主要的公共卫生问题，在英国有近370万人确诊，估计还有100万人没有确诊。肥胖是患2型糖尿病最重要的风险因素，占所有病例的90%。良好的糖尿病管理已被证明可以降低并发症(失明、心脏病、中风、肾脏疾病和截肢)的风险。此外，英国每年的糖尿病护理费用估计高达140亿英镑。所有糖尿病患者在确诊后都应该接受糖尿病自我管理教育和支持，并每年进行强化和评估。不幸的是，在整个英国，推荐和获得这种教育和支持的机会非常不同，每年的强化很少发生。造成这种情况的原因有很多，包括系统容量不足，但也因为许多人不能或不想参加基于课堂的小组会议，直到最近，这一直是获得糖尿病自我管理教育的唯一途径。Mapmy糖尿病可以通过数字渠道提供糖尿病自我管理教育，对糖尿病患者以及提供这种护理的成本和效率产生重大影响。Mapmy糖尿病是一个基于网络的支持平台，它为糖尿病患者提供无限制和持续的教育、支持和自我管理工具，并将他们与他们的医疗保健提供者联系起来，以支持共享的临床决策。由于缺乏临床和成本效益证据基础，NHS正在阻碍Mapmy糖尿病的广泛采用，这使得NHS无法承诺并投入使用这项服务。该项目旨在制定一项数据收集和评估计划，为Mapmy糖尿病形成一个可靠的证据基础，这将为包括NICE、NHS England和临床调试小组在内的关键利益相关者团体所接受。这将使Mapmy糖尿病能够在NHS内部以一定的速度和规模被采用，为糖尿病患者带来真正的好处，并降低向NHS提供服务的成本。“

"Diabetes is a major public health problem with almost 3.7 million people diagnosed in the UK and an estimated 1 million more who are undiagnosed. Obesity is the most significant risk factor for developing type 2 diabetes, which accounts for 90% of all cases. Good diabetes management has been shown to reduce the risk of complications (blindness, heart disease, stroke, kidney disease and amputations). There is also a substantial financial cost to diabetes care, estimated at £14 billion per year in the UK.All people with diabetes should be offered diabetes self-management education and support around the time they are diagnosed, with annual reinforcement and review. Unfortunately, referral and access to this education and support is highly variable across the UK and annual reinforcement rarely happens. There are many reasons for this, including lack of capacity in the system, but also because many people can't, or don't want to attend classroom-based group sessions, which has until recently been the only way to access diabetes self-management education.Mapmydiabetes can make a significant difference to people living with diabetes and to the cost and efficiency of delivering this care by providing diabetes self-management education through digital channels. Mapmydiabetes is a web-based support platform that provides unlimited and ongoing access to education, support and self-management tools for people with diabetes, and also connects them to their healthcare provider to support shared clinical decision-making.The broad adoption of Mapmydiabetes by the NHS is being hindered by lack of a clinical and cost effectiveness evidence base, which prevents the NHS from committing to and commissioning this service. This project aims to develop a data collection and evaluation plan to generate a robust evidence base for Mapmydiabetes that will be acceptable to key stakeholder groups, including NICE, NHS England and Clinical Commissioning Groups. This will enable Mapmydiabetes to be adopted at pace and scale within the NHS to bring real benefits to people living with diabetes as well as reduce the costs of service proviison to the NHS."